Karissa Thal, MD
Family Medicine · Bellefonte, PANPI 1033679691
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $45,907 of the $72,274 with a category attached, or 63.5%. 23 manufacturers reported payments, led by AbbVie at 50.2% of the total. 2025 is the largest year on record at $51,733, more than ten times the $21 reported in 2019. Among family medicine clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 298 payments — averaging $242.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$36K
- Pfizer$33K
- Novo Nordisk$591
- Lilly USA, LLC$550
- GSK$457
- Lundbeck LLC$306
- plus $696 from 17 others
What the payments were for
- Consulting fees$15,03321%
- Speaking & faculty fees$45,90764%
- Travel & lodging$4,7437%
- Food & beverage$6,5759%
- Education$170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 125 | $36,248 |
| Pfizer | 62 | $33,425 |
| Novo Nordisk | 25 | $591 |
| Lilly USA, LLC | 22 | $550 |
| GSK | 16 | $457 |
| Lundbeck LLC | 12 | $306 |
| Teva Pharmaceuticals USA, Inc. | 8 | $153 |
| Amgen | 2 | $75 |
| Impel Pharmaceuticals Inc. | 3 | $64 |
| Dexcom, Inc. | 3 | $63 |
| Tonix Medicines, Inc. | 3 | $54 |
| AstraZeneca(2 entities) | 3 | $45 |
| Exact Sciences | 2 | $38 |
| Neurocrine Biosciences, Inc. | 2 | $34 |
| E.r. Squibb & Sons, L.L.C. | 2 | $29 |
| Genentech USA, Inc. | 1 | $22 |
| Merck | 1 | $21 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $17 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $17 |
| Boehringer Ingelheim | 1 | $17 |
| Amneal Pharmaceuticals LLC | 1 | $16 |
| Upsher-smith Laboratories LLC | 1 | $14 |
| Abbott | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$72,274 in reported general payments places this provider in the 95th percentile of 4,967 family medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| QuliptaAtogepant | 71 | $79,728 |
| JardianceEmpagliflozin | 54 | $57,848 |
| TrulicityDulaglutide | 50 | $54,123 |
| EliquisApixaban | 46 | $49,953 |
| Nurtec OdtRimegepant Sulfate | 30 | $34,539 |
| JanuviaSitagliptin Phosphate | 35 | $34,117 |
| OzempicSemaglutide | 36 | $32,833 |
| UbrelvyUbrogepant | 25 | $26,378 |
| FarxigaDapagliflozin Propanediol | 26 | $25,032 |
| ZavzpretZavegepant Hcl | 18 | $18,096 |
| Emgality PenGalcanezumab-Gnlm | 22 | $15,377 |
| VraylarCariprazine Hcl | 12 | $9,125 |
| TradjentaLinagliptin | 13 | $8,237 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 11 | $7,837 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 13 | $6,306 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieQulipta, Ubrelvy, Vraylar | $36,248 | $115,231108 claims |
| PfizerEliquis, Nurtec Odt, Zavzpret | $33,425 | $102,58894 claims |
| Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat | $17 | $72,39180 claims |
| Lilly USA, LLCTrulicity | $550 | $54,12350 claims |
| MerckJanuvia | $21 | $34,11735 claims |
| Novo NordiskOzempic | $591 | $32,83336 claims |
| AstraZenecaFarxiga, Brilinta | $45 | $30,58539 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $16 | $1,789176 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,967 family medicine providers in Pennsylvania.
Other family medicine in Bellefonte
- Neil SkolnikJenkintown$904K
- Lisa EspinozaNew Hope$722K
- Christopher Varacallodu Bois$627K
- Paul DoghramjiCollegeville$617K
- Brian DeyarminBethel Park$491K
- Nathan BennettPittsburgh$465K
- Gary OwensGlen Mills$404K
- Mary ZakutneyIrwin$393K
- H WilkinsSellersville$380K
- Deborah WittPhiladelphia$226K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.